RE:I dunno about supply chain …I'm sure most shareholders would really enjoy learning more about how PMX benefits Covid patients. You have posted significant evidence of its efficacy and a investigator opinions.
This however is not and never has been a discussion point of management. Covid has been identified as little more than the primary reason for both trial delays.
Outside of your posting there isn't much to discuss. We have been told that they aren't addressing the matter.
Maybe Baxter will see things differently in the future.
Why not is anyone's guess.